BRENZAVVY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Brenzavvy, and when can generic versions of Brenzavvy launch?
Brenzavvy is a drug marketed by Theracosbio and is included in one NDA. There are six patents protecting this drug.
This drug has seventy-one patent family members in thirty-two countries.
The generic ingredient in BRENZAVVY is bexagliflozin. One supplier is listed for this compound. Additional details are available on the bexagliflozin profile page.
DrugPatentWatch® Generic Entry Outlook for Brenzavvy
Brenzavvy will be eligible for patent challenges on January 20, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 20, 2028. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for BRENZAVVY
| International Patents: | 71 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 37 |
| Patent Applications: | 54 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for BRENZAVVY |
| What excipients (inactive ingredients) are in BRENZAVVY? | BRENZAVVY excipients list |
| DailyMed Link: | BRENZAVVY at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BRENZAVVY
Generic Entry Date for BRENZAVVY*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for BRENZAVVY
| Drug Class | Sodium-Glucose Cotransporter 2 Inhibitor |
| Mechanism of Action | Sodium-Glucose Transporter 2 Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for BRENZAVVY
US Patents and Regulatory Information for BRENZAVVY
BRENZAVVY is protected by six US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of BRENZAVVY is ⤷ Try a Trial.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting BRENZAVVY
Crystalline form of benzylbenzene SGLT2 inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
Benzylbenzene derivatives and methods of use
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
Benzylbenzene derivatives and methods of use
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
Crystalline form of benzylbenzene SGLT2 inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting BRENZAVVY
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Theracosbio | BRENZAVVY | bexagliflozin | TABLET;ORAL | 214373-001 | Jan 20, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Theracosbio | BRENZAVVY | bexagliflozin | TABLET;ORAL | 214373-001 | Jan 20, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Theracosbio | BRENZAVVY | bexagliflozin | TABLET;ORAL | 214373-001 | Jan 20, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Theracosbio | BRENZAVVY | bexagliflozin | TABLET;ORAL | 214373-001 | Jan 20, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Theracosbio | BRENZAVVY | bexagliflozin | TABLET;ORAL | 214373-001 | Jan 20, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Theracosbio | BRENZAVVY | bexagliflozin | TABLET;ORAL | 214373-001 | Jan 20, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Theracosbio | BRENZAVVY | bexagliflozin | TABLET;ORAL | 214373-001 | Jan 20, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for BRENZAVVY
See the table below for patents covering BRENZAVVY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Portugal | 2187742 | ⤷ Try a Trial | |
| South Korea | 20100044909 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | ⤷ Try a Trial |
| Australia | 2008288770 | Benzylbenzene derivatives and methods of use | ⤷ Try a Trial |
| Lithuania | 2580225 | ⤷ Try a Trial | |
| South Korea | 20130090875 | CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR | ⤷ Try a Trial |
| European Patent Office | 2187742 | (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-BENZYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL POUR L' UTILISATION DANS LE TRAITEMENT DU DIABETE ((2S,3R,4R,5S,6R)-2-(4-CHLORO-3-BENZYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES) | ⤷ Try a Trial |
| Ukraine | 99924 | ПОХІДНІ БЕНЗИЛБЕНЗОЛУ ТА ЇХ ЗАСТОСУВАННЯ[ПРОИЗВОДНЫЕ БЕНЗИЛБЕНЗОЛА И ИХ ПРИМЕНЕНИЕ (BENZYLBENZOL DERIVATIVES AND USING THEREOF) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
